Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

- Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life …